Metronomic chemotherapy: Back to the future!
- PMID: 20369080
- DOI: 10.1358/dnp.2010.23.2.1475913
Metronomic chemotherapy: Back to the future!
Abstract
Angiogenesis is crucial for the growth of cancer. As such, it has become an established target to fight cancer. Metronomic chemotherapy-the chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule of administration, at close regular intervals, with no prolonged drug-free breaks-is a potential approach to control advanced cancer disease. It is thought to work primarily through antiangiogenic mechanisms and has the property to kill resistant cancer cells and/or to inhibit tumor growth while significantly reducing undesirable toxic side effects. Here, we will discuss potential mechanisms of action of metronomic chemotherapy and briefly review the data regarding the clinical experience with this kind of anticancer treatment. Based on recent insights in the various mechanisms of action, we will try to predict the potential new developments of metronomic chemotherapy in oncology.
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
-
[Metronomic chemotherapy in pediatric oncology: hype or hope?].Arch Pediatr. 2009 Aug;16(8):1158-65. doi: 10.1016/j.arcped.2009.03.019. Epub 2009 May 14. Arch Pediatr. 2009. PMID: 19446445 Review. French.
-
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.Anticancer Res. 2004 May-Jun;24(3a):1759-63. Anticancer Res. 2004. PMID: 15274352
-
Metronomic chemotherapy: teaching old drugs new tricks?Clin Adv Hematol Oncol. 2004 Jul;2(7):432-3. Clin Adv Hematol Oncol. 2004. PMID: 16163217 No abstract available.
-
Metronomic dosing of chemotherapy: applications in pediatric oncology.Cancer Invest. 2006 Jun-Jul;24(4):432-43. doi: 10.1080/07357900600705599. Cancer Invest. 2006. PMID: 16777697 Review.
-
Antiangiogenic scheduling of lower dose cancer chemotherapy.Cancer J. 2001 Sep-Oct;7(5):427-36. Cancer J. 2001. PMID: 11693902 Review.
Cited by
-
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.Nat Rev Clin Oncol. 2016 Nov;13(11):659-673. doi: 10.1038/nrclinonc.2016.64. Epub 2016 May 17. Nat Rev Clin Oncol. 2016. PMID: 27184418 Review.
-
Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.Med Oncol. 2016 Aug;33(8):89. doi: 10.1007/s12032-016-0806-0. Epub 2016 Jul 11. Med Oncol. 2016. PMID: 27400698 Clinical Trial.
-
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.Invest New Drugs. 2018 Aug;36(4):709-714. doi: 10.1007/s10637-018-0579-8. Epub 2018 Feb 27. Invest New Drugs. 2018. PMID: 29488048
-
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Cancer Lett. 2013 Apr 28;330(2):241-9. doi: 10.1016/j.canlet.2012.11.055. Epub 2012 Dec 8. Cancer Lett. 2013. PMID: 23228633 Free PMC article.
-
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Cold Spring Harb Perspect Med. 2012 May;2(5):a006627. doi: 10.1101/cshperspect.a006627. Cold Spring Harb Perspect Med. 2012. PMID: 22553494 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials